We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

225 hedge funds and large institutions have $3.12B invested in IVERIC bio, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 88 increasing their positions, 62 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more funds holding in top 10

Funds holding in top 10: 1019 (+9)

42% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 62

37% more call options, than puts

Call options by funds: $35.3M | Put options by funds: $25.6M

37% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 38

35% more capital invested

Capital invested by funds: $2.31B → $3.12B (+$805M)

6% more funds holding

Funds holding: 213225 (+12)

Holders
225
Holders Change
+12
Holders Change %
+5.63%
% of All Funds
3.62%
Holding in Top 10
19
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+90%
% of All Funds
0.31%
New
52
Increased
88
Reduced
62
Closed
38
Calls
$35.3M
Puts
$25.6M
Net Calls
+$9.61M
Net Calls Change
-$105M
Name Holding Trade Value Shares
Change
Change in
Stake
Swiss National Bank
76
Swiss National Bank
Switzerland
$5.89M +$1.75M +82,000 +42%
UBS Group
77
UBS Group
Switzerland
$5.79M +$3.99M +186,872 +224%
SSA
78
Schonfeld Strategic Advisors
New York
$5.69M +$768K +35,965 +16%
TLP
79
Tri Locum Partners
New York
$5.2M +$1.12M +52,482 +28%
SG Americas Securities
80
SG Americas Securities
New York
$5.13M +$4.7M +220,173 +1,123%
LOAMS
81
Lombard Odier Asset Management (Switzerland)
Switzerland
$5.04M +$3.71M +173,942 +282%
Barclays
82
Barclays
United Kingdom
$5.01M -$2.06M -96,398 -29%
Citadel Advisors
83
Citadel Advisors
Florida
$4.97M -$49.6M -2,326,202 -91%
Schroder Investment Management Group
84
Schroder Investment Management Group
United Kingdom
$4.91M +$4.89M +229,285 New
PC
85
Pier Capital
Connecticut
$4.9M -$68.9K -3,230 -1%
MCM
86
Moore Capital Management
New York
$4.5M -$639K -29,944 -12%
NIP
87
Nicholas Investment Partners
California
$4.5M
BFM
88
Boothbay Fund Management
New York
$4.45M +$596K +27,908 +15%
LCG
89
Lisanti Capital Growth
New York
$4.32M +$4.31M +201,760 New
Alyeska Investment Group
90
Alyeska Investment Group
Illinois
$4.28M +$4.27M +200,000 New
SFM
91
Sphera Funds Management
Israel
$4.19M -$8.24M -386,238 -66%
ACM
92
Altium Capital Management
New York
$4.07M +$1.39M +65,000 +52%
MPAM
93
Monarch Partners Asset Management
Massachusetts
$4M +$1.01M +47,391 +34%
RhumbLine Advisers
94
RhumbLine Advisers
Massachusetts
$3.89M +$552K +25,848 +17%
Citigroup
95
Citigroup
New York
$3.84M -$3.69M -172,698 -49%
Lord, Abbett & Co
96
Lord, Abbett & Co
New Jersey
$3.5M +$3.49M +163,333 New
Manulife (Manufacturers Life Insurance)
97
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.48M +$413K +19,351 +13%
TD Asset Management
98
TD Asset Management
Ontario, Canada
$3.48M +$469K +21,992 +16%
EGI
99
EAM Global Investors
California
$3.47M -$1.15M -54,102 -25%
AG
100
Algert Global
California
$3.36M -$497K -23,310 -13%

ISEE Hedge Fund Activity: Q4 2022 in Review

225 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2022, worth a combined $3.12B — up 35% from $2.31B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new ISEE positions and 38 closed out — a net gain of 14 holders — while 88 added to existing stakes and 62 trimmed.

The largest buyer was Vanguard Group, adding an estimated $86.1M. The largest seller was Janus Henderson Group, cutting an estimated $121M.

  • 225 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2022, up from 213 in Q3 2022.
  • Funds reported $3.12B of IVERIC bio, Inc. Common Stock stock for Q4 2022, up 35% quarter-over-quarter.
  • 52 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2022 and 38 closed out, a net change of +14 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $86.1M added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q4 2022 was Janus Henderson Group, an estimated $121M sold.

Based on aggregated 13F filings for Q4 2022.